BioClonetics Immunotherapeutics: Designing the first cure for HIV through the use of monoclonal antibodies

1

We have created a cell line that produces an anti-HIV antibody called Clone 3.

2

We have demonstrated that Clone 3 neutralizes all clades and groups of HIV isolates.

3

We have identified that Clone 3 targets HIV at an immutable site on the HIV virus.

4

We expect to complete animal trials within 18 to 24 months.

5

We are working with several world-class laboratories who will assist us in conducting the next steps of our plan.

6

1.2 million estimated people die from HIV each year.

7

2 million estimated people are infected with HIV each year.

Joseph P. CotropiaCSO

Southwestern Medical School M.S. Physiological Chemistry B.S. Chemistry Over 45 years of medical research and practice

Tomasz Zastawny, DSc, Ph.D.Chief Clinical Operations Office

Drug Development Executive with 20 years of global, cross-functional experience in Clinical Research, CMC, QA, Regulatory Affairs and Project Management in various therapeutic areas.

Gaurav Chandra

COO & Vice President Research and Development

A qualified Healthcare Professional with 15 years of experience with demonstrated continuous growth, achievements, and impressive leadership within the healthcare industry.

BioClonetics Immunotherapeutics

Designing the first cure for HIV through the use of monoclonal antibodies

$386,766

Highlights

Our Team

Downloads